Marijuana Rescheduling 2026: Order, Deadlines, Timeline Update

Last updated Nov 2, 2026

Short answer: marijuana is not federally legal in 2026, and rescheduling so far covers only state-licensed medical marijuana and FDA-approved products, which moved to Schedule III under an April order. Broader rescheduling of all marijuana is still an administrative process that is on hold until at least November 5.

What happened on October 30, 2026?

Federal registration has started, but only for a narrow group. DEA began issuing registrations to qualifying state-licensed medical marijuana dispensaries. DOJ press release 26-1276 puts the first group at more than 900 dispensaries across seven states, each of which completed DEA’s pre-registration investigation. DOJ calls this the first phase of carrying out the April 23 order issued under 21 U.S.C. 811(d).

DOJ has not named the registered dispensaries, and the Associated Press noted the department did not immediately identify them. DEA’s applicant list gives business types and states, not names. For a patient or supplier, this means a given dispensary’s federal registration is not shown in the DOJ release or the DEA list. DEA continues to process dispensary applications in phases and is reviewing manufacturer and distributor applications, which need facility inspections, production controls and quota decisions.

State licensing alone does not carry automatic federal registration. Applicants must operate under a state medical framework consistent with federal law and treaty obligations, and registered dispensaries take on federal security, recordkeeping and inventory requirements.

Marijuana rescheduling timeline for 2026

Patient and operator framing of the original order is on the medical marijuana Schedule III impact page.

Who counts as a timely applicant, and was April 28 to June 26 the only time to apply?

No. April 28 to June 26 is the expedited, or timely, window. DEA has since opened a new Schedule III registration portal for manufacturers, distributors and laboratories, so the window was not the only route for those entities. Cannabis Business Times reported that DEA will not prioritize applications through the new portal until it has processed the timely applicants.

DEA’s October 30 guidance defines a timely applicant as an entity that submitted a complete application, including the registration fee, between April 28 and June 26, 2026. It excludes applicants who withdrew, applicants denied by a Final Order, and applicants without the required state medical marijuana license. The April final order says DEA will make every effort to process applications filed within 60 days of publication within six months.

What does the November 29 supply-chain date mean?

The guidance expects timely applicants to complete verification and set up compliant supply chains no later than November 29, 2026. For a pending timely applicant, this means it may keep dispensing, manufacturing or distributing schedule III medical marijuana under its state license while DEA reviews the application, and may deal with other timely applicants and with DEA registrants.

The restriction runs the other way. Timely applicants and registrants may not lawfully carry out schedule III medical marijuana activity with entities that did not apply in the window, or have not applied, until those entities are registered. DEA states that dealing with such entities could be grounds for denying an application or revoking a registration.

Due diligence DEA describes for businesses

The guidance lists the minimum checks that generally apply when a business supplies or buys from another:

• From timely dispensers, a copy of the Marijuana Dispensary Information Submission confirmation and verification of the document control number (DCN) on the DEA Diversion Control website.
• From timely manufacturers and distributors, a copy of the submission confirmation and DCN verification.
• From DEA registrants, a copy of the certificate of registration.
• A copy of the entity’s state license, with verification that it is active, plus records of all due diligence.

The DCN check is a business-to-business compliance step. It is not described as a consumer lookup tool. Registrants must keep schedule III records under 21 CFR part 1304, and in a deal with a timely applicant those records may include the DCN where a DEA registration number would otherwise appear.

Inventory and laboratories

Timely dispenser and distributor applicants may keep possessing, dispensing and distributing inventory acquired before the guidance was issued, even if it came from entities that do not qualify. Manufacturers are not named in that allowance. For testing, DEA says it does not intend to penalize sending de minimis quantities to a non-registered analytical laboratory in the same state with detailed records. That applies only in two cases: no laboratory nationwide is registered for the testing, or state law bars out-of-state shipment and no in-state laboratory is registered. Receiving marijuana from a non-registered laboratory is not permitted.

The guidance states that it does not have the force and effect of law and is not meant to bind the public.

Where does the broader DEA rescheduling hearing stand?

The hearing on rescheduling all marijuana ran 11 days and concluded July 15, 2026. On October 22, Judge Julius declined to reopen it for new testimony after the September 23 GAO report, but admitted the report and set briefs due October 29 and replies due November 5, per Cannabis Business Times. The process is on hold until at least November 5.

After that, the judge must certify the record and issue a nonbinding recommendation to DEA Administrator Terry Cole. A recommendation is not a final decision, so for adult-use consumers and businesses the schedule has not changed. Where each track stands is set out in our DEA rescheduling hearing status and timeline.

What did the Minnesota order to show cause say?

On October 30, DEA agents delivered an order to show cause to In-Dispensary in Minneapolis, per the Minnesota Star Tribune. Marijuana Moment reports that Cheri Oz of DEA’s Diversion Control Division signed it. It says Minnesota’s dual-purpose license, which permits both medical and non-medical dispensing, falls outside the new definition of a state medical marijuana license. It also cites veterans who can qualify with identification and an attestation, and Minnesota’s allowance for hemp-derived cannabinoid products.

The document is an order to show cause, not a settled denial. It gives the business two options: request a hearing before an administrative law judge within 30 days, or submit a corrective action plan. DEA’s guidance treats an application as ended only through withdrawal or a Final Order denying it.

Reactions and open points

• The business owner said the agents indicated other recipients were being served the same document that day. No published count of such orders exists.
• Attorney Neil Willner said DEA appears to be testing whether a state can be disqualified as a whole rather than judging individual applicants.
• Gillian Schauer of the Cannabis Regulators Association said state regulators received no notice and that questions remain on how DEA will buy and resell marijuana, coordinate with states and set enforcement priorities.
• Minnesota’s Office of Cannabis Management said the letter does not affect state law and that medical cannabis remains available to patients in the state.
• Cannabis Business Times reports that 30 Minnesota businesses, including 26 dispensaries, filed timely applications; the state’s other 300-plus dispensary licensees did not take part in the expedited process.

Some coverage has described this as DEA rejecting all dual-license applicants. The published record shows one order. The business is named In-Dispensary, not “In-Store.”

Where do the applicants sit, state by state?

DEA’s October 30 list gives business types and states, not names. Cannabis Business Times reported the largest applicant counts below.

The 23 other adult-use states together account for nearly 2,800 timely applicants: 1,769 dispensaries, 707 manufacturers and 289 distributors. Virginia has legalized adult use but has no licensed adult-use market yet. The Associated Press reports that two dozen states plus Washington, D.C. have authorized adult use, 40 states have medical systems, eight others allow low-THC cannabis or CBD oil for medical use, and only Idaho and Kansas ban marijuana outright.

What does registration mean for taxes?

The final order states that state licensees are no longer subject to the Section 280E deduction disallowance as a consequence of the rule, and also states that this is not a determination of federal tax liability. It points qualifying licensees to tax counsel. In an April 23 release, Treasury said Section 280E generally bars deductions for businesses trafficking in Schedule I or II substances and that it and the IRS plan guidance. That guidance is expected to confine 280E to Schedule I or II activity in businesses with several activities and to include a transition rule: rescheduling generally applies from the first full taxable year that includes the order’s effective date. The release does not make DEA registration a stated condition and does not describe relief for earlier years.

For a dual-market business, Minnesota attorney Carol Moss said that operating in a state with both medical and adult-use programs could mean missing the Schedule III tax advantage even when the business sells only medical product. The Associated Press reports that registration could pave the way for tax benefits long denied the industry; the practical treatment depends on Treasury and IRS guidance.

Is marijuana federally legal after the order?

In short, the choice depends on who you are: for a patient, DOJ says it expects broader access to chronic pain treatment, though the effect on patients is not yet established; an adult-use consumer sees no change in federal status, and a licensed medical business should check its timely-applicant status before November 29. The order covers defined medical marijuana activity under a qualifying state license and FDA-approved products. It does not authorize recreational marijuana or other activity outside its scope, and marijuana outside the order stays under Schedule I controls. Registrations do not authorize manufacture, distribution, dispensing or use for non-medical purposes. A registered dispenser may dispense only to individuals state law authorizes to possess marijuana for medical purposes, within the limits of its state license. If a state medical license is suspended, revoked or expires, the DEA registration is automatically suspended.

The same-site explainer what stays illegal after rescheduling covers the boundary in more detail, and federal marijuana law explained addresses the wider confusion between state and federal rules.

What changes on December 11 for hemp?

Hemp is a separate track. According to Vicente LLP, H.R. 6500 moved the federal hemp total THC standard, and the 0.4 milligram total THC per container limit, to December 11, 2026. Public Law 119-37, signed November 12, 2025, amended the hemp definition in section 781. The state-by-state picture for delta-9 products is in the delta-9 state legal guide.

What does this mean for different readers?

What questions are still open?

• Which dispensaries received registrations. DOJ has not named them.
• How many Minnesota-style orders to show cause were issued, and how recipients and states will respond.
• How DEA will buy and resell crops under the order’s nominal-crop-price mechanism, how it will coordinate with states and what enforcement priorities apply, per the Cannabis Regulators Association.
• What requirements DEA may set for owners with criminal histories, which the Associated Press called unclear.
• What benefits registered businesses will have and what problems unregistered ones will face, which MJBizDaily said was not immediately clear.
• When the Administrator will act on the judge’s recommendation, and what the final outcome for adult-use marijuana will be. MJBizDaily reported no clear timeline.
• Whether Treasury and IRS guidance addresses dual-license states, and how, since Treasury’s April release only previews the planned content.

Frequently asked questions

What is the latest marijuana rescheduling update?

DEA issued the first 900-plus dispensary registrations on October 30, 2026, published a timely-applicant list of nearly 7,000 entries and set a November 29 expectation for compliant supply chains. The broader hearing process is on hold until at least November 5.

Is THC rescheduled?

Only within the order’s scope: FDA-approved products containing marijuana and marijuana under a qualifying state medical license moved from Schedule I to Schedule III. Other marijuana remains Schedule I, and hemp follows a separate federal definition with a December 11, 2026 date.

Did the 2026 hearing change the schedule?

No. The hearing concluded July 15, 2026. The judge’s nonbinding recommendation to the DEA Administrator has not yet been made, and the process is on hold until at least November 5.

Has DOT testing changed?

The DOT guide covers that question.

Where can the full order be read?

The final order sets out the definition of a state medical marijuana license and the registration rules at 21 CFR 1301.13(k).

Checklist: the dates and facts to carry forward

• Timely window: April 28 to June 26, 2026; later applications for manufacturers, distributors and laboratories go through a newer portal, which DEA will not prioritize until timely applicants are processed.
• First registrations: October 30, 2026, more than 900 dispensaries in seven states, names not published.
• Supply chains: timely applicants expected to be compliant by November 29, 2026.
• Broader hearing: concluded July 15, 2026; on hold until at least November 5, 2026; then a nonbinding recommendation to the Administrator.
• Minnesota: an order to show cause with a 30-day hearing option or corrective action plan, not a settled denial.
• Hemp: federal date December 11, 2026.
• Adult-use marijuana: still Schedule I; marijuana is not federally legal.

Informational only, not legal, tax or medical advice. Federal and state cannabis rules change, and situation-specific questions belong with a licensed attorney or tax professional. HealthDataConsortium.org is an analytical publication and is not affiliated with any government agency or cannabis industry organization.

Disclosure: This article may contain affiliate links. If a link is clicked and a purchase is made, a commission may be received at no additional cost to the buyer. All opinions remain our own.

By HealthDataConsortium.org Research Team